ValuEngine upgraded shares of KemPharm (NASDAQ:KMPH) from a sell rating to a hold rating in a report published on Friday morning.
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of KemPharm from a hold rating to a buy rating and set a $7.25 price target for the company in a report on Thursday. Oppenheimer reiterated a buy rating on shares of KemPharm in a report on Thursday, March 22nd. Royal Bank of Canada set a $9.00 price target on shares of KemPharm and gave the company a buy rating in a report on Tuesday, January 16th. Roth Capital set a $10.00 price target on shares of KemPharm and gave the company a buy rating in a report on Monday, April 2nd. Finally, Canaccord Genuity set a $11.00 target price on shares of KemPharm and gave the stock a buy rating in a report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. KemPharm currently has an average rating of Buy and an average target price of $10.05.
KemPharm stock opened at $6.28 on Friday. The company has a market capitalization of $94.78, a PE ratio of -2.12 and a beta of -0.34. KemPharm has a twelve month low of $2.45 and a twelve month high of $8.40. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.04). equities research analysts predict that KemPharm will post -2.59 EPS for the current fiscal year.
A hedge fund recently raised its stake in KemPharm stock. Victory Capital Management Inc. increased its holdings in shares of KemPharm (NASDAQ:KMPH) by 26.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 162,077 shares of the specialty pharmaceutical company’s stock after purchasing an additional 34,114 shares during the quarter. Victory Capital Management Inc. owned approximately 1.11% of KemPharm worth $656,000 as of its most recent SEC filing. 36.56% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “KemPharm (KMPH) Rating Increased to Hold at ValuEngine” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/09/kempharm-kmph-rating-increased-to-hold-at-valuengine.html.
KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.